Proposal for a preventive protocol for medication-related osteonecrosis of the jaw

被引:14
作者
Romero-Ruiz, Manuel Ma [1 ]
Romero-Serrano, Marta [1 ]
Serrano-Gonzalez, Ascension [2 ]
Angeles Serrera-Figallo, Maria [1 ]
Luis Gutierrez-Perez, Jose [1 ]
Torres-Lagares, Daniel [1 ]
机构
[1] Univ Seville, Dent Sch, C Avicena S-N, E-41009 Seville, Spain
[2] Hosp Puerta del Mar, Cadiz, Spain
来源
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL | 2021年 / 26卷 / 03期
关键词
Medication-related osteonecrosis of the jaw; clinical protocols; clinical guidelines; prevention; BISPHOSPHONATE-RELATED OSTEONECROSIS; DENTAL IMPLANTS; CANCER-PATIENTS; IMPACT; IMPLEMENTATION; ASSOCIATION; STRATEGIES; EXTRACTION; THERAPY;
D O I
10.4317/medoral.24197
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some patients exposed to certain drugs (antiresorptives such as bisphosphonates or denosumab, and antiangiogenic drugs). From a review of the literature it appears that there is no uniform criterion when selecting preventive measures; these vary according to author. Likewise, the measures recommended are usually general, so that in few cases they result in specific actions to be applied depending on the different variables involved such as the type of drug used, the duration of its application, the underlying pathology, the presence or absence of risk factors, etc. The aim of this study has been to design a preventive protocol which can be easily applied in any clinic or by any dental care service. Material and Methods: We undertook an exhaustive literature review to find any articles related to the topic of study, namely, preventive measures for medication-related osteonecrosis of the jaw, on the one hand generically and on the other focusing on dental implant treatment. The most part the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. From 3946 items, we selected a total of 21 items. Results: From the analysis of the selected articles, several protocols have been developed that are easy to apply in a dental clinic.: Protocol 1. Before starting treatment with antiresorptives (Patients who are going to be treated for osteoporosis / Patients who are going to be treated for cancer). Protocol 2. Once treatment is initiated with antiresorptives (Patients being treated for osteoporosis / Patients being treated for cancer). Conclusions: The application of these protocols requires an interdisciplinary team which can handle the various treatments and apply the measures contained in them. Along with a team of well-educated and trained dentists, it is equally important to maintain contact with the medical team involved in the treatment of the underlying pathology, especially rheumatologists, oncologists, internists and gynaecologists. All the above requires a great staff learning and organization effort, continuous training and coordination of the whole team involved in the preventive management of these patients.
引用
收藏
页码:E314 / E326
页数:13
相关论文
共 38 条
  • [1] Periodontal Disease and Bisphosphonates Induce Osteonecrosis of the Jaws in the Rat
    Aghaloo, Tara L.
    Kang, Ben
    Sung, Eric C.
    Shoff, Michael
    Ronconi, Matthew
    Gotcher, Jack E.
    Bezouglaia, Olga
    Dry, Sarah M.
    Tetradis, Sotirios
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (08) : 1871 - 1882
  • [2] What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis
    Ata-Ali, Javier
    Ata-Ali, Fadi
    Penarrocha-Oltra, David
    Galindo-Moreno, Pablo
    [J]. CLINICAL ORAL IMPLANTS RESEARCH, 2016, 27 (02) : E38 - E46
  • [3] Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis:: A putative role of the Arg-gingipains
    Belibasakis, Georgios N.
    Bostanci, Nagihan
    Hashim, Ahmed
    Johansson, Anders
    Aduse-Opoku, Joseph
    Curtis, Michael A.
    Hughes, Francis J.
    [J]. MICROBIAL PATHOGENESIS, 2007, 43 (01) : 46 - 53
  • [4] Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates
    Bermudez-Bejarano, Elena-Beatriz
    Serrera-Figallo, Maria-Angeles
    Gutierrez-Corrales, Aida
    Romero-Ruiz, Manuel-Maria
    Castillo-de-Oyaguee, Raquel
    Gutierrez-Perez, Jose-Luis
    Machuca-Portillo, Guillermo
    Torres-Lagares, Daniel
    [J]. MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2017, 22 (01): : E43 - E57
  • [5] Interventions for managing medication-related osteonecrosis of the jaw
    Beth-Tasdogan, Natalie H.
    Mayer, Benjamin
    Hussein, Heba
    Zolk, Oliver
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
  • [6] Bonacina R, 2011, J CAN DENT ASSOC, V77, P1
  • [7] Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases
    Bramati, Annalisa
    Girelli, Serena
    Farina, Gabriella
    Dazzani, Maria Chiara
    Torri, Valter
    Moretti, Anna
    Piva, Sheila
    Dimaiuta, Mariastella
    La Verde, Nicla
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2015, 33 (01) : 119 - 124
  • [8] Bisphosphonate treatment and dental implants: A systematic review
    de-Freitas, Nayara-Ribeiro
    Lima, Livia-Bonjardim
    de-Moura, Marcos-Boaventura
    Veloso-Guedes, Cizelene-do-Carmo-Faleiros
    Simamoto-Junior, Paulo-Cesar
    de-Magalhaes, Denildo
    [J]. MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2016, 21 (05): : E644 - E651
  • [9] The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention
    Di Fede, Olga
    Panzarella, Vera
    Mauceri, Rodolfo
    Fusco, Vittorio
    Bedogni, Alberto
    Lo Muzio, Lorenzo
    Sipmo Onj, Board
    Campisi, Giuseppina
    [J]. BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [10] Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
    Dimopoulos, M. A.
    Kastritis, E.
    Bamia, C.
    Melakopoulos, I.
    Gika, D.
    Roussou, M.
    Migkou, M.
    Eleftherakis-Papaiakovou, E.
    Christoulas, D.
    Terpos, E.
    Bamias, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (01) : 117 - 120